We developed retinoic acid-based LYTACs (RATACs) to overcome synthesis and druggability issues. RATACs degrade EGFR, PD-L1, TGF-β, and IgG, showing superior anti-tumor effects in liver and lung cancer models compared to conventional antibodies.